FDA plans risk communication review

Share this article:
A significant effort by FDA is now in "the planning stage," designed to determine how patients, physicians and other healthcare providers obtain information about emerging risks associated with drugs and medical devices, according to Nancy Ostrove, Office of the Commissioner senior advisor for risk communication.

Speaking at a workshop on risk communication in Bethesda, MD, Ostrove said the research study is expected to yield "quantitative as well as qualitative data" on how patients and providers get risk information, as well as their perceptions concerning various formats and means of distribution of public health advisories. The study will include a national survey of providers, and focus groups comprised of patients and consumers.

The need for research to help guide FDA's future risk communication efforts was revealed by the results of a public hearing on the subject, held last December, Ostrove said. Testimony at the hearing criticized the agency's Web site as "too complex" and "difficult to navigate."

More recently, Ostrove said a study of indicated physicians and pharmacists believe that learning about product risks through the popular media (press, television), while rapid, is often simplified, one-sided and unreliable. Information from professional sources (meetings, newsletters, journals) was generally viewed as credible and objective.

While information received from FDA was generally viewed as credible it was often "slower than from other sources"—in some cases even slower than information acquired from professional journals.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...